menu
    • menu

    Company profile for Fermion Oy

    Fermion-PSE
    News
    Fermion & Simcere Enter into Agreement for China's 1st SSTR4 Agonist

    18 Jan 2025

    // PR NEWSWIRE

    Fermion - leader in sustainable API manufacturing

    29 Oct 2024

    // PRESS RELEASE

    Green chemistry at Fermion

    20 Aug 2024

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Fermion VB

    Contact Supplier

    Website

    PharmaVenue

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    https://www.youtube.com/embed/yx_EZVMs2Hw

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    With Fermion, start the journey of your innovative API.

    Related CompaniesRelated Companies

    About

    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Fermion OyFinland Flag
    Country
    Country
    Finland
    Address
    Address
    Koivu-Mankkaan tie 6 A, FI-02200 Espoo
    Telephone
    Telephone
    +358 104261
    Client Email
    Email
    fermionSales@fermion.fi
    Client Website
    Website
    https://www.fermion.fi/
    Linkedin
    Linkedin
    https://fi.linkedin.com/company/fermion-oy
    youtube
    YouTube
    http://www.youtube.com/@fermionoy2799
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-40979.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-1647319060.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2023

    read-more

      https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-43677.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Japan Accreditation Certificate for Oulu Plant

    read-more

      https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-1647319463.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Japan Accreditation Certificate for Hanko Plant

    read-more

      https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-1647319373.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    List of Inspections

    read-more

      https://www.pharmacompass.com/pdf/party/content/fermion-oy-party-content-1647319203.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3230

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Fermion & Simcere Enter into Agreement for China's 1st SSTR4 Agonist
    Fermion & Simcere Enter into Agreement for China's 1st SSTR4 Agonist

    18 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fermion-and-simcere-enter-into-an-exclusive-license-and-collaboration-agreement-for-chinas-first-sstr4-agonist-targeting-pain-302354671.html

    PR NEWSWIRE
    18 Jan 2025
    Share Share
    Fermion - leader in sustainable API manufacturing
    Fermion - leader in sustainable API manufacturing

    29 Oct 2024

    // PRESS RELEASE

    https://www.fermion.fi/who-we-are/news/fermion---leader-in-sustainable-api-manufacturing/#:~:text=Sustainability%20is%20an%20integral%20part,Fermion%20plays%20an%20important%20role.

    PRESS RELEASE
    29 Oct 2024
    Share Share
    Green chemistry at Fermion
    Green chemistry at Fermion

    20 Aug 2024

    // PRESS RELEASE

    https://www.fermion.fi/who-we-are/news/green-chemistry/

    PRESS RELEASE
    20 Aug 2024
    Share Share
    Fermion has completed first investment for new Mfg capacity for APIs
    Fermion has completed first investment for new Mfg capacity for APIs

    12 Mar 2024

    // PRFESS RELEASE

    https://www.fermion.fi/who-we-are/news/fermion-has-completed-first-investment-for-new-manufacturing-capacity-for-apis-at-its-hanko-site/

    PRFESS RELEASE
    12 Mar 2024
    Share Share
    Ami Organics inks agreement with Fermion for two additional APIs
    Ami Organics inks agreement with Fermion for two additional APIs

    19 Dec 2023

    // INDIAN PHARMA POST

    https://www.indianpharmapost.com/news/ami-organics-inks-agreement-with-fermion-for-two-additional-apis-15027

    INDIAN PHARMA POST
    19 Dec 2023
    Share Share
    Fermion has received CEPs for Benserazide HCL and Entacapone
    Fermion has received CEPs for Benserazide HCL and Entacapone

    19 Oct 2023

    // PRESS RELEASE

    https://www.fermion.fi/who-we-are/news/fermion-has-received-ceps-for-benserazide-hcl-and-entacapone/

    PRESS RELEASE
    19 Oct 2023
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Alprazolam

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2020-12-30

    Pay. Date : 2020-12-23

    DMF Number : 9043

    Submission : 1991-04-04

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2007-365 - Rev 01

    Issue Date : 2020-01-13

    Type : Chemical

    Substance Number : 1065

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10128

    Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland

    Initial Date of Registration : 2007-04-18

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-4630

    Start Marketing Date : 1991-04-04

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Azathioprine

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-09-14

    Pay. Date : 2016-08-29

    DMF Number : 5408

    Submission : 1984-03-19

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2006-317 - Rev 02

    Issue Date : 2024-08-23

    Type : Chemical

    Substance Number : 369

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10383

    Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland

    Initial Date of Registration : 2007-12-19

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-0300

    Start Marketing Date : 1997-06-27

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Samil Pharmaceutical Co., Ltd.

    Registration Date : 2022-05-09

    Registration Number : 20220509-209-J-1288

    Manufacturer Name : Fermion Oy, Hangon tehdas

    Manufacturer Address : Orioninkatu 2, Hanko, FI-10900, Finland

     VMF Others AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Formoterol Fumarate

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-09-19

    Pay. Date : 2019-06-25

    DMF Number : 33894

    Submission : 2019-07-12

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2015-215 - Rev 02

    Issue Date : 2023-09-04

    Type : Chemical

    Substance Number : 1724

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 229MF10159

    Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland

    Initial Date of Registration : 2017-08-17

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-4880

    Start Marketing Date : 2016-01-12

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Hydroxychloroquine Sulphate

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-02-26

    Pay. Date : 2016-01-21

    DMF Number : 30014

    Submission : 2015-11-24

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2017-176 - Rev 02

    Issue Date : 2024-01-03

    Type : Chemical

    Substance Number : 2849

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 305MF10090

    Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland

    Initial Date of Registration : 2023-08-02

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-2771

    Start Marketing Date : 2016-01-12

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Irinotecan Hydrochloride

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-09-14

    Pay. Date : 2013-09-05

    DMF Number : 20649

    Submission : 2007-06-29

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2017-236 - Rev 02

    Issue Date : 2023-09-22

    Type : Chemical

    Substance Number : 2675

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 220MF10025

    Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland

    Initial Date of Registration : 2008-01-23

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-4860

    Start Marketing Date : 2007-06-29

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : TNS

    Registration Date : 2022-01-13

    Registration Number : 20220113-210-J-1177

    Manufacturer Name : Fermion Oy

    Manufacturer Address : Laaketehtaantie 2, Oulu, FI-90660, Finland

     VMF Others AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Mercaptopurine

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-07-22

    Pay. Date : 2016-06-23

    DMF Number : 15249

    Submission : 2001-01-15

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2009-074 - Rev 03

    Issue Date : 2021-01-11

    Type : Chemical

    Substance Number : 96

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 218MF10968

    Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland

    Initial Date of Registration : 2006-12-01

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-0299

    Start Marketing Date : 2001-01-15

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Methotrexate

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-06-08

    Pay. Date : 2013-05-23

    DMF Number : 4246

    Submission : 1981-08-06

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2001-145 - Rev 04

    Issue Date : 2018-10-26

    Type : Chemical

    Substance Number : 560

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 219MF10359

    Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland

    Initial Date of Registration : 2007-12-13

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-0491

    Start Marketing Date : 1981-11-19

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF ASMF, BR arrow-down
    ✖
    Available Reg. Filing : ASMF, BR
    AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Sodium Cromoglicate

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2018-06-13

    Pay. Date : 2018-02-08

    DMF Number : 10006

    Submission : 1992-12-15

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2013-136 - Rev 00

    Issue Date : 2021-02-11

    Type : Chemical

    Substance Number : 562

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 223MF10083

    Registrant's Address : Koivu-Mankkaan tie 6A, FI-02200 Espoo, Finland

    Initial Date of Registration : 2011-06-17

    Latest Date of Registration :

    EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-4960

    Start Marketing Date : 1997-01-01

    End Marketing Date : 2024-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Buspirone Hydrochloride

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-07-28

    Pay. Date : 2016-07-21

    DMF Number : 11148

    Submission : 1994-10-21

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2021-262 - Rev 00

    Issue Date : 2022-10-27

    Type : Chemical

    Substance Number : 1711

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-2940

    Start Marketing Date : 1994-10-21

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF Others AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Fluoxetine Hydrochloride

    Finland

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    PharmaVenue
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2014-10-13

    Pay. Date : 2014-10-02

    DMF Number : 11315

    Submission : 1995-01-26

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2009-354 - Rev 02

    Issue Date : 2020-12-21

    Type : Chemical

    Substance Number : 1104

    Status : Valid

     JDMF EU-WC NDC arrow-down
    ✖

    NDC Package Code : 12780-2945

    Start Marketing Date : 1995-01-26

    End Marketing Date : 2026-03-02

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Pharma Science Korea Co., Ltd.

    Registration Date : 2014-10-14

    Registration Number : 20141014-51-C-327-10

    Manufacturer Name : Fermion Oy

    Manufacturer Address : Orioninkatu 2, 10900 Hanko, Finland_x000D_

     VMF Not Available For Sales AUDIT
    fermion

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    ALL Intermediates

    read-more
    read-more
    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    methyl 2-amino-3-hydroxypropanoate hydrochloride

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    5619-04-5
    Benserazide Hydrochloride
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    01

    methyl 2-amino-3-hydroxypropanoate hydrochloride

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    methyl 2-amino-3-hydroxypropanoate hydrochloride

    CAS Number : 5619-04-5

    End Use API : Benserazide Hydrochloride

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    ±2-amino-3-hydroxypropanehydrazide hydrochloride

    Intermediate Web Link

    Market Place

    55819-71-1
    Benserazide Hydrochloride
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    02

    ±2-amino-3-hydroxypropanehydrazide hydrochloride

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    ±2-amino-3-hydroxypropanehydrazide hydrochloride

    CAS Number : 55819-71-1

    End Use API : Benserazide Hydrochloride

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    N-(2-hydroxy-5-((RS)-1-hydroxy-2-(((RS)-1-(4-methoxyphenyl)pro...

    Intermediate Web Link

    Market Place

    73573-87-2
    Formoterol Fumarate
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    03

    N-(2-hydroxy-5-((RS)-1-hydroxy-2-(((RS)-1-(4-methoxyphenyl)propan-2-yl)amino)ethyl)phenyl)formamide

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    N-(2-hydroxy-5-((RS)-1-hydroxy-2-(((RS)-1-(4-methoxyphenyl)pro...

    CAS Number : 73573-87-2

    End Use API : Formoterol Fumarate

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    methyl 1-acetyl-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-c...

    Intermediate Web Link

    Market Place

    1168152-07-5
    Nintedanib Esylate
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    04

    methyl 1-acetyl-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-carboxylate

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    methyl 1-acetyl-3-(methoxy(phenyl)methylene)-2-oxoindoline-6-c...

    CAS Number : 1168152-07-5

    End Use API : Nintedanib Esylate

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide

    Intermediate Web Link

    Market Place

    262368-30-9
    Nintedanib Esylate
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    05

    N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    N-(4-aminophenyl)-N-methyl-2-(4-methylpiperazin-1-yl)acetamide

    CAS Number : 262368-30-9

    End Use API : Nintedanib Esylate

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    9,10-Dehydro Folitixorin Chloride

    Intermediate Web Link

    Market Place

    804563-04-0
    Calcium Folinate
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    06

    9,10-Dehydro Folitixorin Chloride

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    9,10-Dehydro Folitixorin Chloride

    CAS Number : 804563-04-0

    End Use API : Calcium Folinate

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    N-benzyl-6-(4-phenyl-butoxy)hexan-1-amine hydrochloride

    Intermediate Web Link

    Market Place

    163923-18-0
    Salmeterol Xinafoate
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    07

    N-benzyl-6-(4-phenyl-butoxy)hexan-1-amine hydrochloride

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    N-benzyl-6-(4-phenyl-butoxy)hexan-1-amine hydrochloride

    CAS Number : 163923-18-0

    End Use API : Salmeterol Xinafoate

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    9,10-Dehydro Folitixorin Chloride

    Intermediate Web Link

    Market Place

    804563-04-0
    Levoleucovorin Calcium
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    08

    9,10-Dehydro Folitixorin Chloride

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    9,10-Dehydro Folitixorin Chloride

    CAS Number : 804563-04-0

    End Use API : Levoleucovorin Calcium

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Contact Supplier
    • FDA
    • EDQM
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxy...

    Intermediate Web Link

    Market Place

    89365-50-4
    Salmeterol Xinafoate
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together w...
    Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a fully integrated CDMO & offer services covering both APIs & Formulations. API portfolio consists of >30 generic APIs & >10 NCEs & 2 mfg. sites as well as R&D facilities are all located in Finland. Fermion has invested & expanded capabilities in the production of HPAPIs. Drug product CMO services include hormonal & non-hormonal semi-solids, cytotoxic oral solids & packaging. We have 3 mfg. sites & one packaging center for drug products at Orion.
    fermion

    09

    4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxymethyl)phenol

    Finland
    PharmaVenue
    Not Confirmed
    arrow
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothWith Fermion, start the journey of your innovative API.

    Fermion Oy

    4-(1-hydroxy-2-(6-(4-phenylbutoxy)hexylamino)ethyl)-2-(hydroxy...

    CAS Number : 89365-50-4

    End Use API : Salmeterol Xinafoate

    About the Company : Fermion is fully owned subsidiary of Orion Corporation & headquartered in Espoo, Finland. Together with Orion we are a f...

    fermion

    Intermediate Web Link

    Market Place

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    Analytical

    Discover their expertise for : Analytical

    API Manufacturing

    Discover their expertise for : API Manufacturing

    Drug Product Manufacturing

    Discover their expertise for : Drug Product Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    Packaging

    Discover their expertise for : Packaging

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Fermion full-view
    Clinical Phases to Recurrent Production
    full-view
    cGMP Contract Manufacturing of API
    full-view
    Opiate Based Controlled Substances
    full-view
    CDMO for Cytotoxic Compounds
    full-view
    Aseptic Micronization
    full-view
    Gels In Liquid Stick Packs
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Fermion Oy and get a quotation

    Fermion Oy is a supplier offers 38 products (APIs, Excipients or Intermediates).

    Find a price of Alprazolam bulk with DMF, CEP, JDMF offered by Fermion Oy

    Find a price of Azathioprine bulk with DMF, CEP, JDMF offered by Fermion Oy

    Find a price of Formoterol Fumarate bulk with DMF, CEP, JDMF offered by Fermion Oy

    Find a price of Hydroxychloroquine Sulphate bulk with DMF, CEP, JDMF offered by Fermion Oy

    Find a price of Irinotecan Hydrochloride bulk with DMF, CEP, JDMF offered by Fermion Oy

    Find a price of Mercaptopurine bulk with DMF, CEP, JDMF offered by Fermion Oy

    Find a price of Methotrexate bulk with DMF, CEP, JDMF offered by Fermion Oy

    Find a price of Sodium Cromoglicate bulk with DMF, CEP, JDMF offered by Fermion Oy

    Find a price of Buspirone Hydrochloride bulk with DMF, CEP offered by Fermion Oy

    Find a price of Carbidopa bulk with DMF, CEP offered by Fermion Oy

    Find a price of Dexmedetomidine Hydrochloride bulk with DMF, JDMF offered by Fermion Oy

    Find a price of Entacapone bulk with DMF, CEP offered by Fermion Oy

    Find a price of Fluoxetine Hydrochloride bulk with DMF, CEP offered by Fermion Oy

    Find a price of Flutamide bulk with DMF, CEP offered by Fermion Oy

    Find a price of Nadolol bulk with DMF, JDMF offered by Fermion Oy

    Find a price of Nitrofurantoin bulk with DMF, CEP offered by Fermion Oy

    Find a price of Propafenone Hydrochloride bulk with DMF, CEP offered by Fermion Oy

    Find a price of Quetiapine Hemifumarate bulk with DMF, CEP offered by Fermion Oy

    Find a price of Toremifene Citrate bulk with DMF, JDMF offered by Fermion Oy

    Find a price of Benserazide Hydrochloride bulk with CEP offered by Fermion Oy

    Find a price of Budesonide bulk with CEP offered by Fermion Oy

    Find a price of Diltiazem Hydrochloride bulk with DMF offered by Fermion Oy

    Find a price of Glipizide bulk with DMF offered by Fermion Oy

    Find a price of Levosimendan bulk with DMF offered by Fermion Oy

    Find a price of Methotrexate bulk with DMF offered by Fermion Oy

    Find a price of Nintedanib Esylate bulk with DMF offered by Fermion Oy

    Find a price of Nitrofurantoin bulk with DMF offered by Fermion Oy

    Find a price of Ospemifene bulk with DMF offered by Fermion Oy

    Find a price of Quetiapine Hemifumarate bulk with DMF offered by Fermion Oy

    Find a price of Salmeterol Xinafoate bulk with CEP offered by Fermion Oy

    Find a price of Tamsulosin bulk with JDMF offered by Fermion Oy

    Find a price of Tolnaftate bulk with DMF offered by Fermion Oy

    Find a price of Trazodone Hydrochloride bulk with DMF offered by Fermion Oy

    Find a price of Treosulfan bulk with DMF offered by Fermion Oy

    Find a price of Dabrafenib Mesylate bulk offered by Fermion Oy

    Find a price of Osimertinib Mesylate bulk offered by Fermion Oy

    Find a price of Rucaparib Camsylate bulk offered by Fermion Oy

    Find a price of Vismodegib bulk offered by Fermion Oy

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search